Physician profile

John M Huser

Family Medicine · Weatherford, OK

NPI 1861802712

$377.53

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$99.48

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Si-Bone, INC. $145.34 2022
Edwards Lifesciences Corporation $37.43 2024
Novo Nordisk INC $35.30 2020-2021
Astrazeneca Pharmaceuticals LP $31.12 2024 Airsupra
Glaxosmithkline, LLC. $29.16 2021-2022
Lilly USA, LLC $28.64 2022-2023 Emgality, Jardiance
Abbvie INC. $16.02 2023
Merck Sharp & Dohme LLC $15.40 2022
Nestle Healthcare Nutrition INC. $14.03 2022
Bayer Healthcare Pharmaceuticals INC. $13.51 2022
Eisai INC. $11.58 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John M Huser

$377.53

in general payments reported 2019-2025

Years
2020-2024
Top company
Si-Bone, INC.

https://glasscript.com/doctor/5697678/john-m-huser

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.